Estudo Clínico do VM-26 em Associação de Drogas no Tratamento dos Linfomas Malignos, Leucemias e Tumores Sólidos
DOI:
https://doi.org/10.32635/2176-9745.RBC.1977v27n4.3636Palavras-chave:
Teniposídeo/uso terapêutico, Neoplasias/tratamento farmacológico, Quimioterapia CombinadaResumo
O derivado da podofilina, epipodofilotoxina (4'—dimetil—9—(4, 6-0—2—tenilideno — j3 —D-glicopiranosídeo) — VM-26, sintetizado pelo Laboratório SANDOZ, vem sendo amplamente estudado e os resultados têm-se demonstrado favoráveis, principalmente nos linfomas malignos, nas leucemias monocíticas e mielomonocíticas, bem como em alguns tumores sólidos — carcinoma de células transicionais da bexiga, adenocarcinoma do cólon, tumores malignos do ovário, tumores cerebrais e nos derrames malignos cavitários. Os autores apresentam sua experiência nestas neoplasias malignas, excluindo-se apenas os tumores cerebrais da casuística. Os resultados em esquemas de poliquimioterapia parecem indicar a validade do VM—26, embora, em concordância com os demais grupos que vêm estudando a droga, não se tenham obtido remissões completas exclusivamente com o seu uso, mas somente remissões parciais ou mesmo ausência de resposta.
Downloads
Referências
KELLY, M. and Hartwell, J.: The biological effects and Chemical composition of podophyllin. A review. J. Nat. Cancer Inst. 14: 967, 1954.
STAHELIN, H.: VM-26, a new podophyllotoxin glucoside derivati ve with anti L1210 activity. Proc. Amer. Ass. Cancer Res, 10: 86, 1969.
STAHELIN, H.: 4'—demethyl—epipodophyllotoxin thenylidene glucoside (VM-26), a podophylium compound with a new mecanism of action. Europ. J. Cancer. 6: 303, 1970. DOI: https://doi.org/10.1016/0014-2964(70)90095-2
PAVONE-MACALUSO, M., Caramia, G, Rizzo, F.P., Vecchioni, M., Leone, G.: Lo stato attuale delia chemioterapia locoregionale e sistêmica delle neoplasie vesicalli. Gaz. Med. It. 132: 291, 1973
RIVERA, G., AVERY, T. and Pratt, C.: 4'-demethylepipodophyllotoxin 9-(4,6-0—2-thenylidene-B-D-glucopyranoside) (NSC-122819: VM-26) and 4'—demethylepipodophyllotoxin 9—(4,6—0—ethylidene—B—D—glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: Preliminary observations. Cancer Chemother. Rep. Part 1. 59: 743, 1975.
E.O.R.T.C., Co-operative Group for Leukaemias and Haematosarcomas-Clinical Screening of epipodophyllotoxin (VM—26) in malignant lymphomas and solid tumours. Br. Med. J.2:744, 1972. DOI: https://doi.org/10.1136/bmj.2.5816.744
Skalansky, B.D. and cols.: 4'—demethylpodophyllotoxin—B—D—thenylidene glucoside (PTG) in the treatment of malignant intracranial neoplasm. Cancer 33: 460, 1974. DOI: https://doi.org/10.1002/1097-0142(197402)33:2<460::AID-CNCR2820330222>3.0.CO;2-5
Pavone—Macaluso, M. and cols.: Clinical and experimental projects on chemotherapy of bladder tumours. S.A. Med. J. 48: 631, 1974.
Dombernowsky. P. Nissen, N.l. and Larsen, V.: Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethy 1—9—(4,6—0—2-thenylideno—B-D-glucopyranoside) (NSC— 122819), in patients with malignant lymphomas and solid tumours. Cancer Chemother. Rep. Part 1.56: 71. 1972.
MATHÈ, G. and cols.: Essai de traitment de divers hématosarcomes parle 4- déméthylépipodophyllotoxine—B—D—thénylidène glucoside (VM—26 ou EPT). Nouv. Presse Med. 3(8) 447,1974.
KRISHAN, A., Paika, K. and Emil Frei III. Cttofiuorometric studies on the action of podophyllotoxin and epipodophyllotoxin. (VM-26 and VP-16-213) on the cell cycle traverse of human lymphoblasts. The J. of Cell Biol. 66: 521. 1975. DOI: https://doi.org/10.1083/jcb.66.3.521
Muggia, F.M., Selawry, O.S. and Flansen, H.FI.: Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-0-2-thenylidene-B-D-glücopyranoside) (NSC-122819). Cancer Chemoth. Rep. Part 1 55: 575, 1971.
Venditti, J.: Treatment schedule dependency of experimentally active antileukemic L 1210 drugs. Cancer Chemother. Rep. 55: 35, 1971.
E.O.R.T.C.: Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas and solid tumours. Br. Med. J. 3: 199, 1973. DOI: https://doi.org/10.1136/bmj.3.5873.199
MATFIÈ, G. and cols: Two epipodophyllo toxin derivatives, VM-26 and VP 16213, in the treatment of leukemias, hematosarcomas and lymphomas. Cancer 34585, 1974.
Tranekjer, A.S. and Brachetti, A.K.J.: In Vitro behaviour of gynecological tumours against a new podophyllotoxin derivative VM-26. Proc. of the 7th Intern. Cong. of Chemoth. Prague, 1971.
ALLEN, L.M. and Creaven, P.J.: Comparison of the human pharmacokinetics of VM—26 and VP—16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Europ. J. Cancer. 11: 697, 1975. DOI: https://doi.org/10.1016/0014-2964(75)90043-2
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
